October 10, 2016 — BOSTON, MA. and STOCKHOLM, SWEDEN, October 10, 2016  – Aprea Therapeutics AB, a privately held, clinical stage biopharmaceutical company developing novel anticancer therapies targeting the tumor suppressor protein p53, announced today that it enrolled the first patients in the

October 10, 2016 — BOSTON, MA., and STOCKHOLM, SWEDEN, October 10, 2016  – Aprea Therapeutics AB, a privately held, clinical stage biopharmaceutical company developing novel anticancer therapies targeting the tumor suppressor protein p53, today presented clinical data from the Phase Ib part of the

June 16, 2016 — Boston, MA, USA and Stockholm, Sweden, June 16, 2016  – Aprea AB, a privately held, clinical-stage biopharmaceutical company developing novel anticancer therapies targeting the tumor suppressor protein p53, today announced that Christian S.

June 6, 2016 — June 6, 2016, Stockholm, Sweden –  Aprea AB, a privately held, clinical-stage biopharmaceutical company developing novel anticancer therapies targeting the tumor suppressor protein p53, today presented clinical data from the Phase Ib part of the ongoing PiSARRO Phase Ib/II trial in

March 9, 2016 — One of Largest Financings Ever for a Private Scandinavian Biotech Company Participation by Top-Tier International Investors Funds to Support Next Stage of Clinical Development, including Phase II Trial in Ovarian Cancer, for APR-246, First-in-Class Anticancer Compound Reactivating